Drive Wealth Management LLC Sells 1,058 Shares of AstraZeneca PLC (NASDAQ:AZN)

Drive Wealth Management LLC lessened its holdings in shares of AstraZeneca PLC (NASDAQ:AZN) by 24.9% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 3,193 shares of the company’s stock after selling 1,058 shares during the period. Drive Wealth Management LLC’s holdings in AstraZeneca were worth $209,000 as of its most recent SEC filing.

A number of other hedge funds have also recently modified their holdings of the business. Stratos Wealth Advisors LLC boosted its holdings in shares of AstraZeneca by 2.0% during the 3rd quarter. Stratos Wealth Advisors LLC now owns 6,699 shares of the company’s stock valued at $522,000 after buying an additional 133 shares in the last quarter. Crumly & Associates Inc. boosted its holdings in shares of AstraZeneca by 2.2% during the 3rd quarter. Crumly & Associates Inc. now owns 6,644 shares of the company’s stock valued at $518,000 after buying an additional 143 shares in the last quarter. Diversify Wealth Management LLC boosted its holdings in shares of AstraZeneca by 3.6% during the 4th quarter. Diversify Wealth Management LLC now owns 4,402 shares of the company’s stock valued at $295,000 after buying an additional 153 shares in the last quarter. Veery Capital LLC boosted its holdings in shares of AstraZeneca by 4.7% during the 4th quarter. Veery Capital LLC now owns 3,503 shares of the company’s stock valued at $230,000 after buying an additional 157 shares in the last quarter. Finally, Harbour Investments Inc. boosted its stake in AstraZeneca by 1.9% in the 3rd quarter. Harbour Investments Inc. now owns 8,805 shares of the company’s stock worth $686,000 after purchasing an additional 160 shares in the last quarter. Institutional investors own 20.35% of the company’s stock.

Analyst Upgrades and Downgrades

AZN has been the subject of a number of analyst reports. UBS Group upgraded shares of AstraZeneca from a “sell” rating to a “neutral” rating in a research note on Wednesday, November 20th. Deutsche Bank Aktiengesellschaft raised shares of AstraZeneca from a “sell” rating to a “hold” rating in a research report on Wednesday, November 6th. Two investment analysts have rated the stock with a hold rating, five have issued a buy rating and two have given a strong buy rating to the company. According to MarketBeat, AstraZeneca currently has a consensus rating of “Buy” and an average target price of $89.75.

AstraZeneca Trading Up 1.5 %

Shares of NASDAQ:AZN opened at $70.08 on Tuesday. The company has a market cap of $217.32 billion, a P/E ratio of 33.53, a PEG ratio of 1.13 and a beta of 0.46. The company has a debt-to-equity ratio of 0.71, a current ratio of 0.93 and a quick ratio of 0.71. AstraZeneca PLC has a 1 year low of $60.47 and a 1 year high of $87.68. The stock’s fifty day moving average price is $66.44 and its 200-day moving average price is $74.14.

AstraZeneca (NASDAQ:AZN) last announced its quarterly earnings results on Tuesday, November 12th. The company reported $1.04 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.01 by $0.03. The firm had revenue of $13.57 billion for the quarter, compared to the consensus estimate of $13.08 billion. AstraZeneca had a return on equity of 30.01% and a net margin of 12.68%. The company’s quarterly revenue was up 18.0% on a year-over-year basis. During the same period in the prior year, the company posted $0.87 earnings per share. Sell-side analysts expect that AstraZeneca PLC will post 4.12 earnings per share for the current year.

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.